The Efficacy of Baricitinib as a Treatment Option for Alopecia in Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes

Baricitinib, a Janus Kinase inhibitor, has demonstrated significant efficacy in promoting hair regrowth in patients with severe alopecia, as evidenced by improved Severity of Alopecia Tool (SALT) scores in the BRAVE-AA1 and BRAVE-AA2 trials. Patients treated with Baricitinib showed a marked improvement in SALT scores and a higher proportion achieved an absolute SALT score of ≤10 within 36 weeks compared to placebo, with minimal adverse effects reported. The FDA has approved Baricitinib for treating severe alopecia, but further research is needed to assess its long-term safety and confirm these findings in a larger cohort.